London, United Kingdom
Therakind Limited, founded in 2006, is a United Kingdom-based company operating in the Health Care and Pharmaceutical industries. It is dedicated to enhancing access to specialized medicines for children and underserved patient groups through addressing unmet medical needs.
The company stands out for its expertise in designing and developing innovative medicines, from initial development to regulatory approval. By reformulating existing, approved products, Therakind de-risks its clinical programs compared to traditional models, focusing on optimal dosages for specific populations. This approach not only emphasizes safety and efficacy but also aims to improve adherence and disease management.
Key achievements include obtaining marketing authorizations for three pediatric products, including Jylamvo®, an oral methotrexate solution also available for adults. Their development initiatives include the novel DriDose® intranasal dry powder delivery technology.
The company last secured a Venture Round investment from UCLB on 01 January 2015.
